Literature DB >> 4905151

Clinical evaluation of L-asparaginase. Introduction.

J H Burchenal, D A Karnofsky.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1970        PMID： 4905151     DOI： 10.1002/1097-0142(197002)25:2<241::aid-cncr2820250202>3.0.co;2-6

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  5 in total

Review 1.  Cancer chemotherapy--the first twenty-five years.

Authors:  R B Scott
Journal:  Br Med J       Date:  1970-10-31

2.  Tumor inhibitory and non-tumor inhibitory L-asparaginases from Pseudomonas geniculata.

Authors:  G B Kitto; G Smith; T Q Thiet; M Mason; L Davidson
Journal:  J Bacteriol       Date:  1979-01       Impact factor: 3.490

Review 3.  Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future.

Authors:  Vassilios I Avramis; Eduard H Panosyan
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  Purification and properties of L-glutaminase-L-asparaginase from Pseudomonas acidovorans.

Authors:  L Davidson; D R Brear; P Wingard; J Hawkins; G B Kitto
Journal:  J Bacteriol       Date:  1977-03       Impact factor: 3.490

Review 5.  Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia.

Authors:  Vassilios I Avramis; Prakash Nidhi Tiwari
Journal:  Int J Nanomedicine       Date:  2006
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.